ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.00%
US Dollar vs MXN
18.4216
-0.07%
Brent Oil
84.685
-0.01%
Bitcoin
66,194.19
1.89%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Silo Pharma Inc (SILO)

  7. Silo Pharma Inc (SILO) Noticias

SILO Silo Pharma Inc

0.96
0.00 (0.00%)
Pre Mercado
Última actualización: 06:47:38
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Silo Pharma Inc SILO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.96 06:47:38
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.96
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202416:08EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/6/202412:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202415:00EDGAR2Form D - Notice of Exempt Offering of Securities
07/6/202407:18GLOBESilo Pharma Announces Successful Production of its SP-26..
06/6/202415:52EDGAR2Form 8-K - Current report
06/6/202415:50GLOBESilo Pharma Announces Closing of $2 Million Registered..
06/6/202405:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/6/202407:00GLOBESilo Pharma Announces $2 Million Registered Direct Offering..
04/6/202415:05EDGAR2Form 8-K - Current report
04/6/202407:41GLOBESilo Pharma Submits Pre-Investigational New Drug Application..
21/5/202407:45GLOBESilo Pharma Announces Positive Results from Study for..
14/5/202407:45GLOBESilo Pharma to Participate in FDA Meeting Exploring Emerging..
13/5/202415:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/4/202407:15GLOBESilo Pharma Announces Positive Results for Intranasal PTSD..
10/4/202407:11GLOBESilo Pharma set to Acquire Exclusive Licensing for Promising..
20/3/202407:30GLOBESilo Pharma Exercises Option for Exclusive License Agreement..
18/3/202406:15GLOBESilo Pharma Files Patent for Groundbreaking Ketamine Implant..
28/2/202407:25GLOBESilo Pharma Completes Successful Dose-Ranging Study of..
14/2/202407:45GLOBESilo Pharma’s SP-26 Ketamine Implant Demonstrates Successful..
01/2/202412:15EDGAR2Form 8-K - Current report
01/2/202409:00GLOBESilo Pharma Announces Pipeline Prioritization for 2024..
25/1/202416:29EDGAR2Form S-3/A - Registration statement under Securities Act of..
25/1/202416:27EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202407:55GLOBESilo Pharma Announces Positive Results in Alzheimer’s..
23/1/202416:01EDGAR2Form S-3 - Registration statement under Securities Act of..
11/1/202411:15EDGAR2Form 8-K/A - Current report: [Amend]
09/1/202415:30EDGAR2Form 8-K - Current report
04/1/202407:55GLOBESilo Pharma Successfully Completes First Phase of..
28/12/202307:25GLOBESilo Pharma and Partner Receive Regulatory Approval to Begin..
21/12/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:58EDGAR2Form 8-K12B - Notification that a class of securities of..
18/12/202318:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:05EDGAR2Form 8-K - Current report
07/12/202317:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202315:05EDGAR2Form 8-K - Current report
04/12/202315:55EDGAR2Form 8-K - Current report
30/11/202320:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202316:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202307:01GLOBESilo Pharma Enters into Exclusive License Agreement with..
20/11/202318:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202316:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202307:11GLOBESilo Pharma to Initiate Dose-Ranging Study of Novel..
23/10/202316:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/10/202316:00EDGAR2Form DEF 14A - Other definitive proxy statements
16/10/202307:11GLOBESilo Pharma’s SPU-21 Peptide Shows Positive Results Against..
11/10/202307:35GLOBESilo Pharma Initiates Human Factor Study of SPC-15 for the..
10/10/202315:00EDGAR2Form PRE 14A - Other preliminary proxy statements
20/9/202307:28GLOBESilo Pharma Announces Positive Data on SPC-15 for PTSD and..
12/9/202307:50GLOBESilo Pharma Initiates Feasibility Study of SPC-15 Novel..

Su Consulta Reciente

NASDAQ
SILO
Silo Pharma
TG
A2RW4R
International Business M...
AMEX
SCHH
Schwab US REIT
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados